Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients
about
Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trialOxidative stress in schizophreniaN-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of actionUsing glutamate homeostasis as a target for treating addictive disordersCelecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsA Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical CorrelatesThinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signalingFuture clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophreniaNutritional interventions for the adjunctive treatment of schizophrenia: a brief reviewMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaHas an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophreniaOxidative pathways as a drug target for the treatment of autismMechanisms of divalent metal toxicity in affective disordersNegative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS studyCharacterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophreniaA Meta-Analysis of Mismatch Negativity in Schizophrenia: From Clinical Risk to Disease Specificity and ProgressionTargeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia.Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2.Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia.Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamateJuvenile antioxidant treatment prevents adult deficits in a developmental model of schizophreniaMismatch negativity (MMN) as an index of cognitive dysfunctionCortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia.Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls.Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses.How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia.Yi-gan san restores behavioral alterations and a decrease of brain glutathione level in a mouse model of schizophreniaInhibitory interneurons, oxidative stress, and schizophrenia.Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia.Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia.The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia.Gray matter deficits, mismatch negativity, and outcomes in schizophrenia.N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?Research in people with psychosis risk syndrome: a review of the current evidence and future directionsThe relationship between preattentive sensory processing deficits and age in schizophrenia patientsThe glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice.N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic miceGlutamatergic modulation of auditory information processing in the human brain.Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.
P2860
Q21560890-4BB08E2E-A67B-4A2D-9996-F726CB915A15Q24595660-BD7AD794-0AF4-430B-BAC1-546D9793DD8FQ24615952-CE37EB0B-A935-4C5E-BA52-6F66ABB69492Q24619198-D5917EA6-A4EB-4C7E-BE84-8B5939EE41D3Q26741541-3CD2C9C4-39FE-404B-9DBD-20E4CBA30C52Q26786354-3936E7E0-9322-4959-9636-C6EC28793DEDQ26864995-B8F4C3B5-885F-4DEF-B115-77DEFAF3903EQ27014120-96221130-7208-4BD0-BD57-F24750822DF4Q28248117-E67C6781-A469-4A76-8940-4E657A87DABFQ28248687-E45B70BE-274A-4921-A68E-C4ACAEC2D857Q28275290-0F11A88A-D7BC-4778-B4B7-13CBCE384417Q28295948-AE5E6E9F-E107-47FF-976B-61E5C94A1A56Q28384836-7D68935D-36C9-416E-9739-1B88035A1BD5Q28472479-F943DC9B-4EEE-431B-93D0-8E64D7552DE7Q28727584-78793880-687F-4E8C-BC5E-626F694701C9Q30354141-4244DA6D-7378-48B4-93BF-17B2F60972DEQ30380519-CAE8F989-BADD-44EF-90FC-18FAD5A5B752Q30384452-E2891F64-C9AF-4D8C-9812-4B192F63BABDQ30387378-8D392BA2-6FB8-49C9-9F09-1710B5460312Q30394589-FB36AFA7-EF53-4025-97BB-9DD97379EB3CQ30403302-389AF57E-4891-4681-9C1C-836EAA96269DQ30403518-BBF9BE63-EBDE-49FA-9187-DF699050D891Q30407708-7ABD542E-02CF-4E92-A8E4-890198078CB3Q30426629-978EA526-FCD8-489B-A245-91D64E8183BCQ30439309-A1DD147D-6528-4209-95FF-65639C8A7AE3Q30439826-473A7607-FD1F-41D5-B7D7-D967572BC664Q30439924-E5F3E350-A99B-4816-8721-683D2D77F779Q30452926-3DB7392B-74F2-4B07-829F-874014C1A1D1Q30455112-8766F899-9DA4-48D9-9616-0F240761F1B5Q30457809-B179038F-62C9-4BD8-98C2-61F6C4F023A6Q30459211-1CABCC74-273F-45C9-AA08-1B5607984BC1Q30463810-8ADE121B-E067-4C00-8B74-A837EC4D3A82Q30471859-373D357E-828D-4897-9D78-21171FFE3F91Q30474021-5C75A88A-D1D8-491F-8772-2FF9F3D90CBCQ30475598-0A7024F0-4D43-4082-8705-29712A1AF352Q30478849-10627CB9-3F29-4F5C-9C07-54B7D68C6FEBQ30481854-5C6F289C-70F4-4770-824C-9DDBB7E4482EQ30504497-FCDEDF9C-D634-490E-A017-34C622438E25Q30506046-5C4F0BF4-F525-4B6A-A0F9-05B2AD5FD585Q33350202-33C0F7EB-F612-4B7B-955E-2F6880024390
P2860
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Glutathione precursor, N-acety ...... vity in schizophrenia patients
@ast
Glutathione precursor, N-acety ...... vity in schizophrenia patients
@en
Glutathione precursor, N-acety ...... vity in schizophrenia patients
@nl
type
label
Glutathione precursor, N-acety ...... vity in schizophrenia patients
@ast
Glutathione precursor, N-acety ...... vity in schizophrenia patients
@en
Glutathione precursor, N-acety ...... vity in schizophrenia patients
@nl
prefLabel
Glutathione precursor, N-acety ...... vity in schizophrenia patients
@ast
Glutathione precursor, N-acety ...... vity in schizophrenia patients
@en
Glutathione precursor, N-acety ...... vity in schizophrenia patients
@nl
P2093
P2860
P50
P3181
P356
P1476
Glutathione precursor, N-acety ...... vity in schizophrenia patients
@en
P2093
Alessandra Solida
David Copolov
Eleonora Fornari
Maria G Knyazeva
Michel Cuénod
Olivier Boulat
Pascal Vianin
Patricia Deppen
Philippe Conus
Pierre Bovet
P2860
P2888
P304
P3181
P356
10.1038/SJ.NPP.1301624
P407
P577
2008-08-01T00:00:00Z
P5875
P6179
1011937964